Neurogene Inc. Operating Income Loss

• Neurogene Inc. showed a decrease of -25.1% in Operating Income Loss from 2024 to 2025.
• This data is from Neurogene Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Neurogene Inc.'s Operating Income Loss has declined by 174.5%.
• Historical annual values: Fiscal year 2025: -$103.33 million | Fiscal year 2024: -$82.61 million | Fiscal year 2023: -$55.58 million | Fiscal year 2022: -$56.52 million | Fiscal year 2021: -$60.70 million | Fiscal year 2020: -$33.73 million | Fiscal year 2019: -$70.96 million | Fiscal year 2018: -$32.62 million | Fiscal year 2017: -$51.12 million | Fiscal year 2016: -$37.65 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026